Neuropacs Enrolls Dr. Reza Forghani to its Board of Clinical Advisors

Company retains a visionary collaborator for the launch of their innovative software for the diagnostic of Parkinson’s Disease.

GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Reza Forghani, MD, PhD has accepted to serve on neuropacs’ Board of Clinical Advisor, effective immediately.

Dr. Forghani is a member of the University of Florida (UF)’s Intelligent Clinical Care Center (IC3) and the Founder & Director, Advisory Board Chair of the Radiomics and Artificial Intelligence Laboratory (RAIL), as well as a Professor of Radiology & Artificial Intelligence (AI) and Vice Chair of AI at UF. “Dr. Forghani brings unparalleled expertise and forward-thinking insights that promise to revolutionize the future of impactful AI applications in medical imaging” stated Dr. Martin Handfield, neuropacs’ President and CEO. He added: “at neuropacsTM, we believe in the power of collaboration and innovation, and with some of the work we are doing with Dr. Forghani, we’re poised to take significant strides toward shaping the future state of AI in medical imaging. His expertise in end-to-end process of impactful AI development, from inception to workflow integration and adoption, and including the latest technologies such as generative AI and large language models, will undoubtedly propel hospitals adoption of imaging AI models of the future.”

“I’m thrilled with the opportunity to contribute to the development, validation and commercial rollout of neuropacs’ algorythm, and I believe that neuropacs’ novel diagnostic tool has the potential to change how several neurodegenerative diseases will soon be diagnosed, ultimately enabling earlier intervention and improved patient outcomes”, commented Dr. Forghani.

For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.

About neuropacsTM:

neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.

Forward-Looking Statements

This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.